Regulatory science gets boost

The linkurl:National Institutes of Health;http://www.nih.gov/ (NIH) and the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) linkurl:announced a new collaboration;http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201706.htm this morning (Feb 24) that will support efforts in translational and regulatory science, including a contribution of $6.75 million in regulatory research grants over the next three years. Image: Wikimedia commonsSince Margaret Hamburg took the rei

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The linkurl:National Institutes of Health;http://www.nih.gov/ (NIH) and the linkurl:US Food and Drug Administration;http://www.fda.gov/ (FDA) linkurl:announced a new collaboration;http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201706.htm this morning (Feb 24) that will support efforts in translational and regulatory science, including a contribution of $6.75 million in regulatory research grants over the next three years.
Image: Wikimedia commons
Since Margaret Hamburg took the reins as FDA commissioner last year, she has not been shy about her feelings regarding regulatory science -- research that relates the regulatory requirements of biomedical product development to the science that ensures the safety and efficacy of those products. If the production of new therapeutics were a rower, linkurl:Hamburg has said,;http://www.fda.gov/NewsEvents/Speeches/ucm191356.htm it would have one strong arm -- that of fundamental biomedical research and discovery -- but one scrawny arm -- the regulatory science counterpart. And unless the scrawny arm begins to bulk up, the translational side of research will largely just be moving in circles. "Just as biomedical research has evolved in the past decades, regulatory science -- the science and tools we use to assess and evaluate product safety, efficacy, potency, quality and performance -- must also evolve," she said at the annual Regulatory Affairs Professional Society conference last September. (linkurl:See our coverage here.);http://www.the-scientist.com/blog/display/55984/ With today's announcement of the partnership between the NIH and the FDA, it seems Hamburg has got the NIH on her side. After years of working side by side, NIH director Francis Collins said in a meeting announcing the collaboration, and many recent talks with Hamburg at a local diner, the two agencies have finally come together in a collaboration that they call linkurl:"the first of its kind.";http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201706.htm In addition to the funding resources the new initiative will provide, the NIH and FDA are forming a joint leadership council, cochaired by Collins and Hamburg, to help integrate regulatory considerations from the FDA into biomedical research, and conversely, the latest science from the NIH into the regulatory review process. The initiative also plans to reach out to the scientific community, including private and nonprofit organizations bringing medicines to market, to seek input on how the two agencies can work together, starting with a public meeting this spring. The goal of the "new partnership [is] developing more life saving cures and getting them to Americans faster," Health and Human Services Secretary Kathleen Sebelius said at the meeting this morning. "[It] is a great example of our new focus on leveraging all of our assets to reach our highest potential."
**__Related stories:__***linkurl:More regulatory science: FDA chief;http://www.the-scientist.com/blog/display/55984/
[17th September 2009]*linkurl:Report: Collins to lead NIH;http://www.the-scientist.com/blog/display/55733/
[26th May 2009]*linkurl:FDA head chosen, NIH names swirling;http://www.the-scientist.com/blog/display/55507/
[12th March 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio